Expert opinions on prevention, screening, and active surveillance

There are three new and useful resources now available related to the prevention of prostate cancer, screening for prostate cancer, and the role of active surveillance in the expectant management of prostate cancer. … READ MORE …

A guide to PSA screening guidelines

For those who would like to have access to a sound summary of the recommendations of groups around the world on screening for prostate cancer, we can recommend a recent, relatively brief, and straightforward review article recently published in BJU International. … READ MORE …

What a young primary care opinion leader thinks about screening for prostate cancer

In a guest blog post, published yesterday on the MedPage Today web site, Dr. Andrew Buelt, a co-producer of the “Questioning Medicine” podcast for physicians, takes on the issue of screening for prostate cancer. … READ MORE …

D’Amico on the individualization of prostate cancer risk management

In an interesting article in the September 2014 issue of The ASCO Post, Dr. Anthony D’Amico argues in favor of a future in which individualized approaches to risk will replace PSA screening alone as a means of determining who actually needs to be biopsied and (if necessary) receive treatment for clinically significant prostate cancer. … READ MORE …

Cancer screening re-visited again

An article by Melinda Beck in today’s issue of The Wall Street Journal discusses the complex topic of screening, “over-diagnosis”, and over-treatment of low-risk forms of certain cancers (prostate cancer specifically included). … READ MORE …

To quest and test (or not to quest at all)

On The New York Times‘s “Well” blog site today. Dr. Barak Gaster takes on the complex issue of how doctors need to get better at talking to patients about the pros and cons of PSA testing. And there very definitely are pros and cons! I kid you not.

ERSPC mortality data at 13 years of follow-up published

The Lancet has just published previously reported data from the European Randomized Study of Screening for Prostate Cancer (the ERSPC trial) at 13 years of follow-up. These data were first reported earlier this year at the annual meeting of the EAU, and we commented then on the significance of these data. … READ MORE …

Follow

Get every new post delivered to your Inbox.

Join 1,154 other followers